ArticleBMC biology2025
An interpretable geometric graph neural network for enhancing the generalizability of drug-target interaction prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.Briefings in bioinformatics · 2026Article
- Opening the black box: insights into ubiquitin-mediated control of innate antiviral immunity and AI-enhanced therapeutics.Frontiers in immunology · 2026Review
- A Novel Integrative Framework for Depression: Combining Network Pharmacology, Artificial Intelligence, and Multi-Omics with a Focus on the Microbiota-Gut-Brain Axis.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAccurate prediction of drug-target interactions (DTIs) is essential for advancing drug discovery. Although numerous computational methods have been proposed, many exhibit limited generalization, particularly when dealing with unseen drugs or targets.
resultsTo address this challenge, we introduce GPS-DTI, a deep learning framework designed to capture both local and global features of drugs and proteins, thereby enhancing predictive robustness. Specifically, GPS-DTI employs a graph isomorphism network with edge features (GINE)-based graph neural network, combined with a multi-head attention mechanism (MHAM), to effectively model the structural characteristics of drug molecules. For proteins, representations are derived from the pre-trained Evolutionary Scale Model (ESM-2) model and further refined through convolutional neural networks (CNNs), yielding rich feature embeddings. A cross-attention module integrates drug and protein features, uncovering biologically meaningful interactions and improving model interpretability.
conclusionsComprehensive benchmarking across in-domain and cross-domain DTI prediction tasks demonstrates that GPS-DTI outperforms existing methods, underscoring its strong generalization capability. Notably, the model achieves state-of-the-art performance on drug-target affinity (DTA) tasks and shows robust adaptability when evaluated on an independent Coronavirus Disease 2019 (COVID-19)-related test set. Furthermore, visualization of cross-attention maps offers interpretable insights into key molecular interactions, highlighting the potential of GPS-DTI in real-world drug discovery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.